Associate Director of National Intelligence and Chief Information Officer

SpartanNash Promotes Tyler King to VP, Finance

Retrieved on: 
Monday, August 23, 2021
Food, Beverage, Other Retail, Retail, Supermarket, Convenience Store, People, General manager, District, D&W Fresh Market, EVP, D, MDV, SPTN, Multimedia, Senior, Saginaw Valley State University, Family Fare, SpartanNash, Monaco, Borders Group, VP, Supermarket, Associate Director of National Intelligence and Chief Information Officer, Management

Grocery retailer and distributor SpartanNash (Nasdaq: SPTN) today announced Tyler King has been promoted from Senior Director to Vice President, Finance and Finance Business Partner for the Companys retail business segment.

Key Points: 
  • Grocery retailer and distributor SpartanNash (Nasdaq: SPTN) today announced Tyler King has been promoted from Senior Director to Vice President, Finance and Finance Business Partner for the Companys retail business segment.
  • View the full release here: https://www.businesswire.com/news/home/20210823005376/en/
    SpartanNash Promotes Tyler King to VP, Finance (Photo: Business Wire)
    In his new role, King will serve as an advisor for the retail business segment, led by Executive Vice President and General Manager, Corporate Retail Tom Swanson .
  • King will provide strategic insights to support SpartanNashs 148 retail stores in attaining financial goals and company objectives.
  • Since then, he has served as Director, Retail Inventory (2015-2018), Director, Retail Accounting (2018-2020) and most recently, Senior Director, Finance (2020-2021).

Recipes for Trial Acceleration & Improved Patient Engagement Through Comprehensive, Integrated Mobile Clinical Services, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, August 23, 2021
SME, Industry, Associate, Clinical trial, Head, Acceleration, Associate Director of National Intelligence and Chief Information Officer, Food, Patient, Global Operations, Pharmaceutical industry

The speakers will also demonstrate how the move to greater digitization of source data can improve quality and reduce the need for manual data entry.

Key Points: 
  • The speakers will also demonstrate how the move to greater digitization of source data can improve quality and reduce the need for manual data entry.
  • For more information, or to register for this event, visit Recipes for Trial Acceleration & Improved Patient Engagement Through Comprehensive, Integrated Mobile Clinical Services.
  • Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.
  • Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.)

LUMICKS Appoints Paul Wheeler to Leadership Team as Chief Commercial Officer to Drive New Business Growth

Retrieved on: 
Tuesday, August 17, 2021
Molecule, Industry, General manager, STED, Chemistry, Vrije Universiteit Amsterdam, Leadership, Pharma, Merck, Research, Physics, Marketing, RND, Biology, Nobel Prize, Head, Optical tweezers, Flow cytometry, EMEA, Associate Director of National Intelligence and Chief Information Officer, Management, Microscope

AMSTERDAM, Aug. 17, 2021 /PRNewswire/ --LUMICKS, a leading next generation life science tools company, is pleased to announce the appointment of Dr. Paul Wheeler to its leadership team, effective July 1, 2021.

Key Points: 
  • AMSTERDAM, Aug. 17, 2021 /PRNewswire/ --LUMICKS, a leading next generation life science tools company, is pleased to announce the appointment of Dr. Paul Wheeler to its leadership team, effective July 1, 2021.
  • In the newly-created position of Chief Commercial Officer, Dr. Wheeler will lead LUMICKS aggressive commercial growth strategy by building a stronger market presence, developing highly-effective sales teams, and focusing on enhanced customer success.
  • Dr. Wheeler brings 20 years of sales experience to LUMICKS, most recently with LUMINEX as Vice President of Flow Cytometry and General Manager EMEA.
  • Dr. Wheeler also brings in-depth experience in managing marketing, RnD and operations teams, as well as expertise in mergers and acquisitions.

LUMICKS Appoints Paul Wheeler to Leadership Team as Chief Commercial Officer to Drive New Business Growth

Retrieved on: 
Tuesday, August 17, 2021
Molecule, Industry, General manager, STED, Chemistry, Vrije Universiteit Amsterdam, Leadership, Pharma, Merck, Research, Physics, Marketing, RND, Biology, Nobel Prize, Head, Optical tweezers, Flow cytometry, EMEA, Associate Director of National Intelligence and Chief Information Officer, Management, Microscope

AMSTERDAM, Aug. 17, 2021 /PRNewswire/ -- LUMICKS, a leading next generation life science tools company, is pleased to announce the appointment of Dr. Paul Wheeler to its leadership team, effective July 1, 2021. In the newly-created position of Chief Commercial Officer, Dr. Wheeler will lead LUMICKS aggressive commercial growth strategy by building a stronger market presence, developing highly-effective sales teams, and focusing on enhanced customer success. 

Key Points: 
  • AMSTERDAM, Aug. 17, 2021 /PRNewswire/ --LUMICKS, a leading next generation life science tools company, is pleased to announce the appointment of Dr. Paul Wheeler to its leadership team, effective July 1, 2021.
  • In the newly-created position of Chief Commercial Officer, Dr. Wheeler will lead LUMICKS aggressive commercial growth strategy by building a stronger market presence, developing highly-effective sales teams, and focusing on enhanced customer success.
  • Dr. Wheeler brings 20 years of sales experience to LUMICKS, most recently with LUMINEX as Vice President of Flow Cytometry and General Manager EMEA.
  • Dr. Wheeler also brings in-depth experience in managing marketing, RnD and operations teams, as well as expertise in mergers and acquisitions.

Kinnate Biopharma Inc. Reports Second Quarter 2021 Financial Results

Retrieved on: 
Monday, August 16, 2021
RAF, FGFR, Melanoma, U.S. Securities and Exchange Commission, MAPK, Clinical trial, Drug, SAN, Foresite Capital, Lung cancer, Cancer, COVID-19, IND, GLOBE, Pharmacokinetics, SEC, Skin cancer, Research, Security (finance), Board, Patient, Investment, Growth, Corporate development, Sarah Cannon Research Institute, Risk, Board of directors, MPH, BRAF, KNTE, Nasdaq, Safety, Society, Class II, Therapy, Associate Director of National Intelligence and Chief Information Officer, Industry, ASCO, Corporation, Cryptocurrency, Pharmaceutical industry, Management, Lithium

SAN FRANCISCO and SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced financial results for the quarter ended June 30, 2021. The company also announced that the first patient has commenced treatment in its Phase 1 KN-8701 clinical trial evaluating its lead RAF product candidate, KIN-2787, a pan-RAF inhibitor being developed for the treatment of patients with lung cancer, melanoma and other solid tumors.

Key Points: 
  • Ended the quarter with cash, cash equivalents and investments of $365.1 million, exclusive of $35.0 million in its China joint venture
    SAN FRANCISCO and SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced financial results for the quarter ended June 30, 2021.
  • Second quarter net loss for 2021 was $21.4 million, compared to $7.6 million for the same period in 2020.
  • Second quarter research and development expenses for 2021 were $16.2 million, compared to $5.6 million for the same period in 2020.
  • Second quarter general and administrative expenses for 2021 were $5.3 million, compared to $2.0 million for the same period in 2020.

The Wall Street Technology Association (WSTA) and Nemertes Announce Executive TechTalks for Financial Technology and Business Professionals

Retrieved on: 
Thursday, August 5, 2021
Zero, Cloud, Chief executive officer, Committee, Founder, Collaboration, Digital, Industry, Associate Director of National Intelligence and Chief Information Officer, S, Americas, Technology, Organization, WSTA, Digital News, WFH, Prudential, Bajaj Finserv, Security, Prudential Financial, EquiLend, Association, Integrity management, Morgan Stanley, TD, Digital transformation, Management, Life insurance

NEW YORK, Aug. 5, 2021 /PRNewswire-PRWeb/ --The Wall Street Technology Association (WSTA) , a not-for-profit organization that provides financial technology and business professionals a forum to learn from and connect with each other and Nemertes , a global research-based advisory and consulting firm that analyzes the business value of emerging technologies, are pleased to announce a new on-demand video series, Executive TechTalks.

Key Points: 
  • NEW YORK, Aug. 5, 2021 /PRNewswire-PRWeb/ --The Wall Street Technology Association (WSTA) , a not-for-profit organization that provides financial technology and business professionals a forum to learn from and connect with each other and Nemertes , a global research-based advisory and consulting firm that analyzes the business value of emerging technologies, are pleased to announce a new on-demand video series, Executive TechTalks.
  • In this new offering, FinServ executives, from some of the world's top financial firms, discuss their technology tribulations and triumphs around six industry relevant and timely topics targeted to the financial services industry.
  • Executive TechTalks is a video series of candid conversations with Industry Leaders providing unprecedented insights into relevant topics of interest to financial services firms.
  • Nemertes is a global research-based advisory and consulting firm that analyzes the business value of emerging technologies.